X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ORCHID PHARMA LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ORCHID PHARMA LTD CIPLA/
ORCHID PHARMA LTD
 
P/E (TTM) x 44.6 -0.5 - View Chart
P/BV x 3.8 0.4 1,047.8% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 CIPLA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
ORCHID PHARMA LTD
Sep-13
CIPLA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs622194 320.6%   
Low Rs45835 1,309.4%   
Sales per share (Unadj.) Rs181.9276.5 65.8%  
Earnings per share (Unadj.) Rs12.9-79.2 -16.2%  
Cash flow per share (Unadj.) Rs29.3-43.5 -67.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.753.9 288.6%  
Shares outstanding (eoy) m804.5170.45 1,142.0%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.00.4 717.1%   
Avg P/E ratio x42.0-1.4 -2,903.1%  
P/CF ratio (eoy) x18.4-2.6 -699.2%  
Price / Book Value ratio x3.52.1 163.4%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,5168,067 5,386.7%   
No. of employees `00023.02.8 823.0%   
Total wages/salary Rs m26,3382,527 1,042.3%   
Avg. sales/employee Rs Th6,349.16,956.1 91.3%   
Avg. wages/employee Rs Th1,143.0902.5 126.6%   
Avg. net profit/employee Rs Th449.3-1,993.0 -22.5%   
INCOME DATA
Net Sales Rs m146,30219,477 751.2%  
Other income Rs m2,287407 561.6%   
Total revenues Rs m148,58919,884 747.3%   
Gross profit Rs m24,7581,103 2,245.4%  
Depreciation Rs m13,2292,519 525.1%   
Interest Rs m1,5945,227 30.5%   
Profit before tax Rs m12,222-6,236 -196.0%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m1,798-125 -1,435.8%   
Profit after tax Rs m10,354-5,580 -185.5%  
Gross profit margin %16.95.7 298.9%  
Effective tax rate %14.72.0 732.6%   
Net profit margin %7.1-28.7 -24.7%  
BALANCE SHEET DATA
Current assets Rs m87,37011,014 793.2%   
Current liabilities Rs m33,08132,060 103.2%   
Net working cap to sales %37.1-108.1 -34.3%  
Current ratio x2.60.3 768.8%  
Inventory Days Days8795 91.7%  
Debtors Days Days6234 185.7%  
Net fixed assets Rs m111,56729,440 379.0%   
Share capital Rs m1,609705 228.4%   
"Free" reserves Rs m123,6452,043 6,053.3%   
Net worth Rs m125,2543,800 3,296.2%   
Long term debt Rs m36,4549,018 404.2%   
Total assets Rs m209,53246,510 450.5%  
Interest coverage x8.7-0.2 -4,488.5%   
Debt to equity ratio x0.32.4 12.3%  
Sales to assets ratio x0.70.4 166.7%   
Return on assets %5.7-0.8 -750.2%  
Return on equity %8.3-146.9 -5.6%  
Return on capital %8.5-3.7 -227.6%  
Exports to sales %34.237.9 90.3%   
Imports to sales %8.322.6 36.9%   
Exports (fob) Rs m50,0507,378 678.4%   
Imports (cif) Rs m12,2034,406 277.0%   
Fx inflow Rs m51,0667,513 679.7%   
Fx outflow Rs m17,6785,649 313.0%   
Net fx Rs m33,3881,865 1,790.7%   
CASH FLOW
From Operations Rs m23,8241,682 1,416.6%  
From Investments Rs m-13,127-9,860 133.1%  
From Financial Activity Rs m-13,2396,644 -199.3%  
Net Cashflow Rs m-2,478-1,535 161.4%  

Share Holding

Indian Promoters % 16.0 32.3 49.5%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 4.6 265.2%  
FIIs % 23.7 3.3 718.2%  
ADR/GDR % 1.1 4.6 23.9%  
Free float % 26.2 55.3 47.4%  
Shareholders   161,166 84,811 190.0%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare CIPLA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 21, 2018 03:35 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS